GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hunan Er-Kang Pharmaceutical Co Ltd (SZSE:300267) » Definitions » Goodwill-to-Asset

Hunan Er-Kang Pharmaceutical Co (SZSE:300267) Goodwill-to-Asset : 0.00 (As of Mar. 2024)


View and export this data going back to 2011. Start your Free Trial

What is Hunan Er-Kang Pharmaceutical Co Goodwill-to-Asset?

Goodwill to Asset ratio measures how much goodwill a company is recording compared to the total level of its assets. Hunan Er-Kang Pharmaceutical Co's Goodwill for the quarter that ended in Mar. 2024 was ¥2 Mil. Hunan Er-Kang Pharmaceutical Co's Total Assets for the quarter that ended in Mar. 2024 was ¥5,462 Mil. Therefore, Hunan Er-Kang Pharmaceutical Co's Goodwill to Asset Ratio for the quarter that ended in Mar. 2024 was 0.00.


Hunan Er-Kang Pharmaceutical Co Goodwill-to-Asset Historical Data

The historical data trend for Hunan Er-Kang Pharmaceutical Co's Goodwill-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hunan Er-Kang Pharmaceutical Co Goodwill-to-Asset Chart

Hunan Er-Kang Pharmaceutical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Goodwill-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Hunan Er-Kang Pharmaceutical Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Goodwill-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Hunan Er-Kang Pharmaceutical Co's Goodwill-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Hunan Er-Kang Pharmaceutical Co's Goodwill-to-Asset, along with its competitors' market caps and Goodwill-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hunan Er-Kang Pharmaceutical Co's Goodwill-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Hunan Er-Kang Pharmaceutical Co's Goodwill-to-Asset distribution charts can be found below:

* The bar in red indicates where Hunan Er-Kang Pharmaceutical Co's Goodwill-to-Asset falls into.



Hunan Er-Kang Pharmaceutical Co Goodwill-to-Asset Calculation

Goodwill to Asset ratio measures how much goodwill a company is recording compared to the total level of its assets.

It is calculated by dividing goodwill by total assets.

Hunan Er-Kang Pharmaceutical Co's Goodwill to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Goodwill to Asset (A: Dec. 2023 )=Goodwill/Total Assets
=2/5479.069
=0.00

Hunan Er-Kang Pharmaceutical Co's Goodwill to Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

Goodwill to Asset (Q: Mar. 2024 )=Goodwill/Total Assets
=2/5461.857
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Hunan Er-Kang Pharmaceutical Co  (SZSE:300267) Goodwill-to-Asset Explanation

If the goodwill-to-asset ratio increases, it can mean that the company is recording a proportionately higher amount of goodwill, assuming total assets are remaining constant. It is generally good to see a company increasing its assets regularly; however, if these increases are coming from intangible assets, such as goodwill, the increases may not be as good.

Increases in the goodwill-to-asset ratio might suggest that a company has been aggressively acquiring other firms or has seen its tangible assets decrease in value. When a large portion of total assets are attributable to intangible assets (such as goodwill), the company may be at risk of having that portion of its asset base wiped out quickly if it must record any goodwill impairments. Decreases in the goodwill-to-assets ratio suggest that the company has either written down some goodwill or increased its tangible assets.

Asset needs vary from industry to industry. This is why comparing goodwill-to-assets ratios is generally most meaningful among companies within the same industry. By comparing a company's goodwill to assets ratio to those of other companies within the same industry, investors can get a feel for how a company is managing its goodwill.


Hunan Er-Kang Pharmaceutical Co Goodwill-to-Asset Related Terms

Thank you for viewing the detailed overview of Hunan Er-Kang Pharmaceutical Co's Goodwill-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Hunan Er-Kang Pharmaceutical Co (SZSE:300267) Business Description

Traded in Other Exchanges
N/A
Address
Kangping Road 167, National Economic and Technological Development Zone, Liuyang Changsha, Hunan, CHN, 410331
Hunan Er-Kang Pharmaceutical Co Ltd develops, produces and sells pharmaceutical products in China. The company's main products include pharmaceutical excipients and antibiotics. It offers pharmaceutical excipients, APIs and finished drug products. The pharmaceutical excipients include products such as glycerol, ethanol pharmaceutically, acceptable propylene glycol, sodium hydroxide, and pharmaceutically acceptable sugar. The company's finished drugs primarily include sulbenicillin sodium for injection and compound liquorice tablets. Its APIs include glycerin, dilute hydrochloric acid, dihydroxypropyl theophylline, sulbenicillin sodium, calamine powder, sulfadiazine, sulphaguanidine, TMP, and resorcinol. Geographically, all the activities are carried out through China.

Hunan Er-Kang Pharmaceutical Co (SZSE:300267) Headlines

No Headlines